Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Novel Cell-Based Bioassays for Monoclonal Antibody and Bispecific Molecules in PD-1 Blockade Monotherapy and Combination Therapy

Part # PS428


We have developed a suite of MOA-based reporter bioassays designed for PD-1 blockade monotherapy as well as PD-1 in combination with a second immune checkpoint receptor. They overcome the limitations of primary cell-based assays and can be used for antibody screening, characterization, potency and stability studies. These bioassays provide the following:

  • Biologically relevant measurement of antibody MOA
  • Consistent and reliable thaw-and-use format
  • Easy implementation, rapid results

Printed in USA.